NCT05488314 2026-03-13
METalmark
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
Clinical Trials
3 trialsNCT03040973 2026-02-02
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
Novartis
Phase 2 Active not recruiting
NCT03333343 2026-01-16
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
Novartis
Phase 1 Active not recruiting